December 2025: Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Description
Dr. Suresh Durgam (Intra-Cellular Therapies, a Johnson & Johnson Company, Bedminster, NJ) joins AJP Audio to discuss a phase 3 randomized controlled trial looking at the use of the antipsychotic medication lumateperone as adjunctive to antidepressant therapy in the treatment of patients with major depressive disorder. Afterwards, AJP Editor-in-Chief Dr. Ned Kalin discusses the rest of the December issue of the Journal.
- 00:48 Durgam interview
- 03:09 Mechanism of action
- 04:44 Patient-reported outcomes
- 06:31 Immediate clinical implications
- 07:32 Limitations
- 08:08 Further research
- 09:25 Kalin interview
- 09:38 Durgam et al.
- 13:09 Lin et al.
- 17:22 Brodsky et al.
Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Spotify, or wherever you listen to it.
Subscribe to the podcast here.
Listen to other podcasts produced by the American Psychiatric Association.
Browse articles online.
How authors may submit their work.
Follow the journals of APA Publishing on Twitter.
E-mail us at ajp@psych.org
United States
